{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:52:21Z","timestamp":1790628741141,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11883-022-01071-1","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T09:06:42Z","timestamp":1668157602000},"page":"959-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-3621","authenticated-orcid":false,"given":"Farzahna","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-7041","authenticated-orcid":false,"given":"Brett S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"4","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/CIRCRESAHA.115.306398","volume":"118","author":"K Musunuru","year":"2016","unstructured":"Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579\u201385. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306398.","journal-title":"Circ Res"},{"issue":"9493","key":"1071_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists\u2019 (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1.","journal-title":"Lancet"},{"issue":"8","key":"1071_CR3","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/jc.2018-00470","volume":"103","author":"GA Nichols","year":"2018","unstructured":"Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemia patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103(8):3019\u201327. https:\/\/doi.org\/10.1210\/jc.2018-00470.","journal-title":"J Clin Endocrinol Metab"},{"issue":"40","key":"1071_CR4","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"\u2022\u2022 Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, Vupanorsen Study Investigators, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridemia. Eur Heart J. 2020;41(40):3936\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa689. (Phase 2 study in patients with hypertriglyceridemia, diabetes and hepatic steatosis showed an improvement in the lipid profile with the ASO, Vupanorsen, compared to placebo.)","journal-title":"Eur Heart J"},{"issue":"4","key":"1071_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249.","journal-title":"Circ Res"},{"issue":"47","key":"1071_CR6","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"\u2022 Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2013a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551. (Consensus statement providing an updated therapeutic paradigm of targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.)","journal-title":"Eur Heart J"},{"issue":"2","key":"1071_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-022-00520-2","volume":"36","author":"NC Ward","year":"2022","unstructured":"\u2022 Ward NC, Chan DC, Watts GF. A tale of two new targets for hypertriglyceridemia: which choice of therapy? BioDrugs. 2022;36(2):121\u201335. https:\/\/doi.org\/10.1007\/s40259-022-00520-2. (A review of the etiology and treatment of hypertriglyceridemia, with a focus on the therapeutic role of ANGPTL3 and apoC-III inhibition.)","journal-title":"BioDrugs"},{"issue":"1","key":"1071_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2019.05.023","volume":"30","author":"SG Young","year":"2019","unstructured":"Young SG, Fong LG, Beigneux AP, Allan CM, He C, et al. GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab. 2019;30(1):51\u201365. https:\/\/doi.org\/10.1016\/j.cmet.2019.05.023.","journal-title":"Cell Metab"},{"issue":"1","key":"1071_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cmet.2010.04.016","volume":"12","author":"BS Davies","year":"2010","unstructured":"Davies BS, Beigneux AP, Barnes RH 2nd, Tu Y, Gin P, Weinstein MM, et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 2010;12(1):42\u201352. https:\/\/doi.org\/10.1016\/j.cmet.2010.04.016.","journal-title":"Cell Metab"},{"issue":"4","key":"1071_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbrc.2008.12.018","volume":"379","author":"H Adachi","year":"2009","unstructured":"Adachi H, Fujiwara Y, Kondo T, Nishikawa T, Ogawa R, Matsumura T, et al. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem Biophys Res Commun. 2009;379(4):806\u201311. https:\/\/doi.org\/10.1016\/j.bbrc.2008.12.018.","journal-title":"Biochem Biophys Res Commun"},{"issue":"37","key":"1071_CR11","doi-asserted-by":"publisher","first-page":"33742","DOI":"10.1074\/jbc.M203215200","volume":"277","author":"T Shimizugawa","year":"2002","unstructured":"Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277(37):33742\u20138. https:\/\/doi.org\/10.1074\/jbc.M203215200.","journal-title":"J Biol Chem"},{"issue":"12","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13(12):731\u20139. https:\/\/doi.org\/10.1038\/nrendo.2017.119.","journal-title":"Nat Rev Endocrinol"},{"issue":"43","key":"1071_CR13","doi-asserted-by":"publisher","first-page":"41804","DOI":"10.1074\/jbc.M302861200","volume":"278","author":"M Ono","year":"2003","unstructured":"Ono M, Shimizugawa T, Shimamura M, Yoshida K, Noji-Sakikawa C, Ando Y, et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem. 2003;278(43):41804\u20139. https:\/\/doi.org\/10.1074\/jbc.M302861200.","journal-title":"J Biol Chem"},{"issue":"9","key":"1071_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"\u2022 Adam RC, Mintah IJ, Alexa-Braun CA, Shihanian LM, Lee JS, Banerjee P, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res. 2020;61(9):1271\u201386. https:\/\/doi.org\/10.1194\/jlr.RA120000888. (Research showing that ANGPTL3 inhibition promotes VLDL processing and clearance via an EL-dependent mechanism.)","journal-title":"J Lipid Res"},{"issue":"3","key":"1071_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1006\/geno.1999.6041","volume":"62","author":"D Conklin","year":"1999","unstructured":"Conklin D, Gilbertson D, Taft DW, Maurer MF, Whitmore TE, Smith DL, et al. Identification of a mammalian angiopoietin-related protein expressed specifically in liver. Genomics. 1999;62(3):477\u201382. https:\/\/doi.org\/10.1006\/geno.1999.6041.","journal-title":"Genomics"},{"issue":"2","key":"1071_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ng814","volume":"30","author":"R Koishi","year":"2002","unstructured":"Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet. 2002;30(2):151\u20137. https:\/\/doi.org\/10.1038\/ng814.","journal-title":"Nat Genet"},{"issue":"37","key":"1071_CR17","doi-asserted-by":"publisher","first-page":"26410","DOI":"10.1074\/jbc.M113.501304","volume":"288","author":"R Essalmani","year":"2013","unstructured":"Essalmani R, Susan-Resiga D, Chamberland A, Asselin MC, Canuel M, Constam D, et al. Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes. J Biol Chem. 2013;288(37):26410\u20138. https:\/\/doi.org\/10.1074\/jbc.M113.501304.","journal-title":"J Biol Chem"},{"issue":"1","key":"1071_CR18","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1038\/s41598-020-73388-3","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Zhang Y, Zhang M, Wang Y. GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice. Sci Rep. 2020;10(1):16168. https:\/\/doi.org\/10.1038\/s41598-020-73388-3.","journal-title":"Sci Rep"},{"issue":"4","key":"1071_CR19","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","volume":"321","author":"KL Sylvers-Davie","year":"2021","unstructured":"Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab. 2021;321(4):E493\u2013508. https:\/\/doi.org\/10.1152\/ajpendo.00195.2021.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"48","key":"1071_CR20","doi-asserted-by":"publisher","first-page":"19751","DOI":"10.1073\/pnas.1217552109","volume":"109","author":"F Quagliarini","year":"2012","unstructured":"Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012;109(48):19751\u20136. https:\/\/doi.org\/10.1073\/pnas.1217552109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1071_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1021\/acschembio.0c00954","volume":"16","author":"N Jin","year":"2021","unstructured":"\u2022 Jin N, Matter WF, Michael LF, Qian Y, Gheyi T, Cano L, et al. The angiopoietin-like protein 3 and 8 complex interact with lipoprotein lipase and induces LPL cleavage. ACS Chem Biol. 2021;16(3):457\u201362. https:\/\/doi.org\/10.1021\/acschembio.0c00954. (This study demonstrated the mechanism by which ANGPTL3 inhibits LPL.)","journal-title":"ACS Chem Biol"},{"key":"1071_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bbrc.2020.11.053","volume":"534","author":"YQ Chen","year":"2021","unstructured":"Chen YQ, Pottant TG, Siegel RW, Ehsani M, Qian Y-W, Roell WC, Konrad RJ. Angiopoietin-like protein 4(E40K) ANGPTL4\/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4. Biochem Biophys Res Commun. 2021;534:498\u2013503.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1071_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2796.1991.tb00304.x","volume":"229","author":"S Fazio","year":"1991","unstructured":"Fazio S, Sidoli A, Vivenzio A, Maietta A, Giampaoli S, Menotti A, et al. A form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene. J Intern Med. 1991;229(1):41\u20137. https:\/\/doi.org\/10.1111\/j.1365-2796.1991.tb00304.x.","journal-title":"J Intern Med"},{"issue":"23","key":"1071_CR24","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220\u20137. https:\/\/doi.org\/10.1056\/NEJMoa1002926.","journal-title":"N Engl J Med"},{"issue":"3","key":"1071_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1612790.","journal-title":"N Engl J Med"},{"issue":"12","key":"1071_CR26","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1194\/jlr.P039875","volume":"54","author":"I Minicocci","year":"2013","unstructured":"Minicocci I, Santini S, Cantisani V, Stitziel N, Kathiresan S, Arroyo JA, Mart\u00ed G, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013;54(12):3481\u201390. https:\/\/doi.org\/10.1194\/jlr.P039875.","journal-title":"J Lipid Res"},{"key":"1071_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","volume":"268","author":"Y-X Xu","year":"2018","unstructured":"Xu Y-X, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A, Deik A, Trindade K, Wang X, Musunuru K, Clish CB, Cowan C, Fizgerald K, Rader D, Kathiresan S. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoproteins. Atherosclerosis. 2018;268:196\u2013206. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.08.031.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1071_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1172\/JCI37118","volume":"119","author":"S Romeo","year":"2009","unstructured":"Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119(1):70\u20139. https:\/\/doi.org\/10.1172\/JCI37118.","journal-title":"J Clin Invest"},{"issue":"16","key":"1071_CR29","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, PROMIS and Myocardial Infarction Genetics Consortium Investigators, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.030.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1071_CR30","doi-asserted-by":"publisher","first-page":"7310","DOI":"10.3390\/ijms22147310","volume":"22","author":"PY Chen","year":"2021","unstructured":"Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. Int J Mol Sci. 2021;22(14):7310. https:\/\/doi.org\/10.3390\/ijms22147310.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1071_CR31","doi-asserted-by":"publisher","first-page":"E1299","DOI":"10.1210\/jc.2015-1254","volume":"100","author":"PA Nidhina Haridas","year":"2015","unstructured":"Nidhina Haridas PA, Soronen J, S\u00e4devirta S, Mysore R, Quagliarini F, Pasternack A, et al. Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin. J Clin Endocrinol Metab. 2015;100(10):E1299\u2013307. https:\/\/doi.org\/10.1210\/jc.2015-1254.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1071_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.bbrc.2004.08.024","volume":"322","author":"M Shimamura","year":"2004","unstructured":"Shimamura M, Matsuda M, Ando Y, Koishi R, Yasumo H, Furukawa H, et al. Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor. Biochem Biophys Res Commun. 2004;322(3):1080\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2004.08.024.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1071_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2796.2010.02305.x","volume":"269","author":"C Pramfalk","year":"2011","unstructured":"Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011;269(3):333\u20139. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02305.x.","journal-title":"J Intern Med"},{"key":"1071_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2020.11.013","volume":"315","author":"LF Reeskamp","year":"2020","unstructured":"\u2022 Reeskamp LF, Tromp TR, Huijgen R, Stroes ESG, Hovingh GK, Grefhorst A. Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. Atherosclerosis. 2020;315:68\u201375. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.11.013. (This study showed that statins reduce ANGPTL3 levels by 15%.)","journal-title":"Atherosclerosis"},{"issue":"1","key":"1071_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785.","journal-title":"Eur Heart J"},{"issue":"4","key":"1071_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364\u201373.","journal-title":"JAMA"},{"key":"1071_CR37","doi-asserted-by":"publisher","unstructured":"\u2022 Watts GF, Raal FJ, Chan DC. Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiol. 2022;18(2):143\u201353. https:\/\/doi.org\/10.2217\/fca-2021-0096. (Review of the functional role of ANGPTL3 in lipid\nmetabolism and the rationale for the development of targeted\nnucleic acid therapies to ANGPTL3, supported by clinical\ntrial data.)","DOI":"10.2217\/fca-2021-0096"},{"issue":"6","key":"1071_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","volume":"32","author":"S Kersten","year":"2021","unstructured":"Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol. 2021;32(6):335\u201341. https:\/\/doi.org\/10.1097\/MOL.0000000000000789.","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"1071_CR39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1194\/jlr.M054890","volume":"56","author":"V Gusarova","year":"2015","unstructured":"Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308\u201317. https:\/\/doi.org\/10.1194\/jlr.M054890.","journal-title":"J Lipid Res"},{"key":"1071_CR40","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, ELIPSE HoFH Investigators, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215. (ELIPSE HoFH study, studying the use of evinacumab, a monoclonal antibody to ANGPTL3, showed up to a 50% reduction in LDL-C in HoFH patients, even in those with null-null LDLR receptor mutations.)","DOI":"10.1056\/NEJMoa2004215"},{"issue":"3","key":"1071_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296\u20137. https:\/\/doi.org\/10.1056\/NEJMc1705994.","journal-title":"N Engl J Med"},{"key":"1071_CR42","doi-asserted-by":"publisher","first-page":"A12066","DOI":"10.1161\/circ.144.suppl_1.12066","volume":"144","author":"FJ Raal","year":"2021","unstructured":"\u2022 Raal FJ, Rosenson RS, Reeskamp LF, Kastelein JJ, Rubba P, Duell B, et al. The longer-term efficacy of evinacumab in patients with homozygous familial hypercholesterolemia. Circulation. 2021;144:A12066. https:\/\/doi.org\/10.1161\/circ.144.suppl_1.12066. (Post hoc analysis of the ELIPSE HoFH study showed long-term efficacy of evinacumab, whereby 32% achieved an LDL-C <70 mg\/dL (<1.8 mmol\/L).)","journal-title":"Circulation"},{"issue":"24","key":"1071_CR43","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"\u2022\u2022 Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2031049. (Evinacumab reduced LDL-C by more than 50% in HeFH and non-FH patients on maximal lipid-lowering therapy.)","journal-title":"N Engl J Med"},{"issue":"3","key":"1071_CR44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1701329.","journal-title":"N Engl J Med"},{"issue":"18","key":"1071_CR45","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"\u2022 Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, TRANSLATE-TIMI 70 Investigators, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059266. (Vupanorsen, at escalating doses, in adults with hyperlipidemia, showed a modest reduction in LDL-C, with a dose-dependent increase in liver enzymes and hepatic fat.)","journal-title":"Circulation"},{"key":"1071_CR46","first-page":"e987","volume":"140","author":"GF Watts","year":"2019","unstructured":"Watts GF, Schwabe C, Scott R, Gladding P, Sullivan DR, Baker J, et al. RNA interference targeting hepatic & angiopoietin-like protein 3 results in prolonged reductions in plasma triglycerides and LDL-C in human subjects. Circulation. 2019;140:e987\u20138.","journal-title":"Circulation"},{"key":"1071_CR47","doi-asserted-by":"publisher","unstructured":"\u2022 Watts GF, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia. Eur Heart J. 2020;41(2):ehaa946.3331. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3331. (Sequential doses of an siRNA against ANGPTL3 administered to healthy volunteers dropped ANGPTL3 levels by more than 80% leading to a lowering of TG > 60% and LDL-C >45%.)","DOI":"10.1093\/ehjci\/ehaa946.3331"},{"issue":"16","key":"1071_CR48","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.3390\/ijms22168422","volume":"22","author":"WS Siew","year":"2021","unstructured":"Siew WS, Tang YQ, Kong CK, Goh BH, Zacchigna S, Dua K, et al. Harnessing the potential of CRISPR\/Cas in atherosclerosis: disease modeling and therapeutic applications. Int J Mol Sci. 2021;22(16):8422. https:\/\/doi.org\/10.3390\/ijms22168422.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1071_CR49","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","volume":"115","author":"Q Ding","year":"2014","unstructured":"Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115(5):488\u201392. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.304351.","journal-title":"Circ Res"},{"key":"1071_CR50","doi-asserted-by":"publisher","unstructured":"\u2022 Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334. https:\/\/doi.org\/10.1038\/s41586-021-03534-y. (Proof-of-concept study in nonhuman primates showing that CRISPR base editing lowers PCSK9 and LDL-C by 90% and 60% respectively.)","DOI":"10.1038\/s41586-021-03534-y"},{"issue":"9","key":"1071_CR51","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","volume":"137","author":"AC Chadwick","year":"2018","unstructured":"Chadwick AC, Evitt NH, Lv W, Musunuru K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation. 2018;137(9):975\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031335.","journal-title":"Circulation"},{"issue":"14","key":"1071_CR52","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.vaccine.2013.02.001","volume":"31","author":"MF Bachmann","year":"2013","unstructured":"Bachmann MF, Whitehead P. Active immunotherapy for chronic diseases. Vaccine. 2013;31(14):1777\u201384. https:\/\/doi.org\/10.1016\/j.vaccine.2013.02.001.","journal-title":"Vaccine"},{"key":"1071_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pharmtox-061008-103129","volume":"49","author":"GT Jennings","year":"2009","unstructured":"Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol. 2009;49:303\u201326. https:\/\/doi.org\/10.1146\/annurev-pharmtox-061008-103129.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"39","key":"1071_CR54","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1093\/eurheartj\/ehab299","volume":"42","author":"A Sahebkar","year":"2021","unstructured":"Sahebkar A, Momtazi-Borojeni AA, Banach M. PCSK9 vaccine: so near, yet so far! Eur Heart J. 2021;42(39):4007\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehab299.","journal-title":"Eur Heart J"},{"issue":"12","key":"1071_CR55","doi-asserted-by":"publisher","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","volume":"9","author":"G Galabova","year":"2014","unstructured":"Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairhofer A, et al. Peptide-based anti-PCSK9 vaccines \u2013 an approach for long-term LDLc management. PLoS ONE. 2014;9(12):e114469. https:\/\/doi.org\/10.1371\/journal.pone.0114469.","journal-title":"PLoS ONE"},{"issue":"43","key":"1071_CR56","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","volume":"33","author":"E Crossey","year":"2015","unstructured":"Crossey E, Amar MJA, Sampson M, Peabody J, Schiller JT, Chackerian B, et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine. 2015;33(43):5747\u201355. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.044.","journal-title":"Vaccine"},{"issue":"40","key":"1071_CR57","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1016\/j.vaccine.2021.08.077","volume":"39","author":"A Fowler","year":"2021","unstructured":"Fowler A, Sampson M, Remaley AT, Chackerian B. A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice. Vaccine. 2021;39(40):5780\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.077.","journal-title":"Vaccine"},{"key":"1071_CR58","doi-asserted-by":"publisher","unstructured":"\u2022 Fukami H, Morinaga J, Nakagami H, Hayashi H, Okadome Y, Matsunaga E, et al. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Rep Med. 2021;2(11):100446. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100446. (A peptide vaccine against ANGPTL3 in mouse models of dyslipidemia durably lowered TG and LDL-C for 30\u00a0weeks.)","DOI":"10.1016\/j.xcrm.2021.100446"},{"issue":"3","key":"1071_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MOL.0000000000000679","volume":"31","author":"LF Reeskamp","year":"2020","unstructured":"\u2022 Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020;31(3):140\u20136. https:\/\/doi.org\/10.1097\/MOL.0000000000000679. (Review of the role of apoC-III and ANGPTL3 in triglyceride metabolism.)","journal-title":"Curr Opin Lipidol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01071-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:19:20Z","timestamp":1744208360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01071-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01071-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"15 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FJR has received research grants, honoraria, or consulting fees for professional input and\/or delivered lectures from Sanofi-Aventis, Regeneron, Amgen, Novartis, and LIB Therapeutics. FM and BSM have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Human Research Ethics Committee, University of the Witwatersrand, Johannesburg, South Africa; Reference number: 180214) and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}